BSE Live
Dec 26, 16:01Prev. Close
2194.25
Open Price
2195.25
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 26, 15:55Prev. Close
2193.30
Open Price
2206.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
2193.00 (238)
| Profit & Loss account of Mankind Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 4,730.15 | 3,871.41 | 3,921.76 | 3,511.78 | 3,171.28 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 5.36 | 18.86 | 22.55 | |
| Revenue From Operations [Net] | 4,730.15 | 3,871.41 | 3,916.40 | 3,492.92 | 3,148.73 | |
| Total Operating Revenues | 4,794.41 | 3,877.49 | 3,918.14 | 3,507.06 | 3,149.51 | |
| Other Income | 93.85 | 64.33 | 200.88 | 89.37 | 72.73 | |
| Total Revenue | 4,888.26 | 3,941.82 | 4,119.01 | 3,596.43 | 3,222.24 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 434.87 | 216.32 | 140.34 | 123.58 | 128.98 | |
| Purchase Of Stock-In Trade | 1,182.55 | 1,115.85 | 1,213.18 | 1,283.43 | 1,088.64 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -44.51 | 22.08 | 77.25 | -111.25 | -12.60 | |
| Employee Benefit Expenses | 991.47 | 785.02 | 798.01 | 662.72 | 573.89 | |
| Finance Costs | 10.62 | 39.04 | 17.94 | 1.40 | 1.45 | |
| Depreciation And Amortisation Expenses | 61.77 | 38.39 | 27.52 | 18.60 | 36.70 | |
| Other Expenses | 986.57 | 1,033.83 | 912.01 | 836.35 | 731.53 | |
| Total Expenses | 3,623.34 | 3,250.53 | 3,186.24 | 2,814.82 | 2,548.59 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 1,264.92 | 691.30 | 932.77 | 781.61 | 673.65 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 1,264.92 | 691.30 | 932.77 | 781.61 | 673.65 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 336.58 | 187.46 | 256.70 | 218.58 | 206.01 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -35.11 | -10.20 | -10.09 | 24.82 | -1.55 | |
| Tax For Earlier Years | 5.23 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 306.70 | 177.26 | 246.61 | 243.39 | 204.45 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 958.23 | 514.04 | 686.16 | 538.22 | 469.20 | |
| Profit/Loss From Continuing Operations | 958.23 | 514.04 | 686.16 | 538.22 | 469.20 | |
| Profit/Loss For The Period | 958.23 | 514.04 | 694.36 | 538.22 | 469.20 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 23.92 | 12.83 | 17.33 | 268.71 | 234.25 | |
| Diluted EPS (Rs.) | 23.92 | 12.83 | 17.33 | 268.71 | 234.25 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 302.44 | 24.04 | 300.44 | 0.00 | 300.44 | |
| Tax On Dividend | 61.82 | 4.89 | 35.58 | 0.00 | 60.82 | |
| Equity Dividend Rate (%) | 755.00 | 4.00 | 750.00 | 0.00 | 1,500.00 |
12.11.2025
Mankind Pharma Standalone September 2025 Net Sales at Rs 2,608.78 crore, up 3.12% Y-o-Y
11.11.2025
07.11.2025
Mankind Pharma Consolidated September 2025 Net Sales at Rs 3,697.16 crore, up 20.17% Y-o-Y
07.11.2025
12.11.2025
Mankind Pharma Standalone September 2025 Net Sales at Rs 2,608.78 crore, up 3.12% Y-o-Y
07.11.2025
Mankind Pharma Consolidated September 2025 Net Sales at Rs 3,697.16 crore, up 20.17% Y-o-Y
01.08.2025
Mankind Pharma Consolidated June 2025 Net Sales at Rs 3,570.35 crore, up 23.4% Y-o-Y
01.08.2025
Mankind Pharma Standalone June 2025 Net Sales at Rs 2,541.36 crore, up 5.75% Y-o-Y